10th Annual World Patient Safety, Science & Technology Summit Begins
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/
Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)
Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospitals. We’re all humans, we’re all a little bit competitive, and I think you react to data. This will make a difference.”
In a keynote address, Don Berwick, MD, MPP, FRCP, former administrator of the Centers for Medicare and Medicaid Services, pointed out that one in four hospital patients experience injury as a result of their care.
“Healthcare is far too unsafe,” said Berwick. “A large proportion of patient safety problems can be eliminated. There are hospitals in this nation that have driven certain kinds of infections to zero and virtually eliminated the risk of pneumonia from ventilation machines.”
Berwick suggested that healthcare systems can learn from many of the safety practices that the aviation industry has successfully put in place. “Today, you would have to fly continuously on a commercial flight for over 6,000 years to have a 50:50 chance of being injured as a passenger,” he said. “Roughly speaking, that means you are more than two million times safer in an airplane seat than in a hospital.”
Jannicke Mellin-Olsen, former president of the World Federation of Societies of Anesthesiologists, used her keynote address to call for more healthcare systems to involve patients and family members of those who have suffered harm in order to help drive better practices. “Involvement means hearing the patient voice at every level of the service,” she said.
The first day of the Summit also featured a talk from Sir Liam Donaldson, former chief medical officer of the United Kingdom, who discussed the impact of Covid-19 on patient safety and how the pandemic illustrated the lack of resilience throughout our healthcare structures. “There wasn’t much thinking about patient safety in the pandemic planning that preceded Covid,” said Donaldson. “Failures to develop world-class infection control facilities put both health workers and patients at risk, but there was also the issue of transitions of care, which greatly affected elderly patients and led to the virus spreading through nursing homes. That should have been part of our thinking from a patient safety perspective.”
Neelam Dhingra, who heads the World Health Organization’s (WHO) Transformative Flagship Initiative, emphasized the need to improve patient safety in low- and middle-income countries. Dhingra pointed out how when WHO conducted a survey of 102 countries in 2022, just 27% had developed a national patient safety action plan, and only 18% had established national targets on reducing medication-related harm.
“In low- and middle-income countries, we are still very far from even simple procedures when it comes to patient safety,” said Dhingra. “Studies from these countries are limited, but the estimates we have suggest that every minute at least five patients die in hospital. This means that the burden of harm in healthcare is grossly underestimated.”
Konrad Reinhart, founding president of the Global Sepsis Alliance, highlighted the continuing need to improve public awareness on sepsis and push for hospitals to comply with best practices. “Given the number of sepsis deaths worldwide, which are higher than cancer, the potential to reduce harm is enormous,” he said.
There were additional talks from world-renowned patient safety champion Peter Pronovost, along with Stephanie Mercado, chief executive officer of the National Association for Healthcare Quality, and Peter Lachman who leads the PSMF’s Fellowship Program. Tedros Adhanom Ghebreyesus, director general of WHO, addressed the Summit in a prerecorded video message.
Panel discussions included contributions from members of the President’s Council of Advisors on Science and Technology regarding their upcoming report on patient safety, as well as an assessment from healthcare leaders on the potential of predictive analytics and AI to improve patient safety.
Other panels touched on subjects ranging from the need for patient and family engagement in healthcare to proposals for forming a National Patient Safety Board. The day’s program ended with a private screening of the HBO documentary Bleed Out.
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601006140/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
